REPLY: “From Cloud to Edge” Research Predicts the Rise of Edge Computing and Unveils the Main Trends in the Cloud Computing Market
2.2.2021 12:00:00 EET | Business Wire | Press release
By 2025 Cloud Computing will lead the ICT infrastructure market and Edge Computing will become an exponentially growing market, according to Reply’s new research “From Cloud to Edge”, made possible by Reply’s Trend SONAR proprietary data-driven platform and the support of Teknowlogy Group.
The research explores the use of both Cloud Computing and Edge Computing technologies in “Europe-5” (Italy, Germany, France, Netherlands, Belgium), and “Big-5” (USA, United Kingdom, Brazil, China, India) clusters in order to understand the evolution of the market.
In the next 5 five years Edge Computing will be an exponentially growing market in all “Europe-5” and “Big-5” clusters’ countries. Germany will be the biggest European market for both Cloud Computing and Edge Computing; the USA will be the dominant market worldwide.
The growing usage of IoT solutions, the closer combination of Information Technology and Operational Technology and the integration of Industrial Control Systems in the IT stack, as well as future 5G campus solutions for low-latency applications, are accelerating the need for edge solutions.
In fact, Edge Computing can support companies with computing tasks that cannot be done in the cloud and offers clear advantages when dealing with low latency, connectivity, security or privacy and transmitted data volumes are an issue.
Edge and distributed cloud architectures will increase the speed of data processing and reduce time lag. Edge computing, alone or in combination with Cloud Computing, will play a key role to enable technologies like autonomous vehicles, digital factories, smart cities, digital health, smart tracking and much more.
Hybrid models like Edge Cloud will be pushed by the hyperscalers and the wide 5G rollout will give Telcos and their service partners a relevant role in the new ecosystem, especially thanks to mobile-edge computing which is able to ensure very low latency without local infrastructure, with compute units not on-premise but extremely close from to a cell tower.
“Edge computing is here to stay. It is already starting to reshape enterprise computing and it can play a vital role in IT architectures. All the industries that need to perform the computing tasks as close to where data is gathered as possible will benefit from Edge Computing. At Reply, we’re already supporting global enterprises to design and implement architectures that leverage the best of Edge and Cloud Computing, while ensuring privacy and cybersecurity” commented Filippo Rizzante, CTO Reply.
In addition, the research indicates that Cloud Computing became the most popular ICT focus during Coronavirus peaks. COVID-19 has intensified the global spread of Cloud Computing technologies after 15 years of steady growth: across the world, millions of users started to use cloud-based platforms to collaborate, shop online, and for entertainment purposes.
Cloud technologies are key to being able to react and restart activities. By 2021 in both “Europe-5” and “Big-5” clusters the Infrastructure as a Service (IaaS)/Platform as a Service (PaaS) market will grow - in all scenarios - between 50% and 55% (vs. 2019).
The Software as a Service (SaaS) market is also set to grow rapidly in every country analysed. In particular, by 2025 it is predicted to double in the USA, UK and all “Europe-5” cluster countries, while likely to quadruple in India and China.
For more insights download the full research “From Cloud To Edge”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005054/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom